Uterine serous carcinoma: Increased familial risk for lynch-associated malignancies

Cancer Prevention Research

Volumn 5, Issue 3, 2012, Pages 435-443

  Dewdney, Summer B ^a   Kizer, Nora T ^a   Andaya, Abegail A ^b   Babb, Sheri A ^a   Luo, Jingqin ^a   Mutch, David G ^a   Schmidt, Amy P ^a   Brinton, Louise A ^b   Broaddus, Russell R ^c   Ramirez, Nilsa C ^d   Huettner, Phyllis C ^a   McMeekin, Donald Scott ^f   Darcy, Kathleen ^g   Ali, Shamshad ^g   Judson, Patricia L ⁱ   Mannel, Robert S ^f   Lele, Shashikant B ^h   O'Malley, David M ^e   Goodfellow, Paul J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NATIONWIDE CHILDREN S HOSPITAL   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^g Statistical and Data Center   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER INCIDENCE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; FEMALE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUMAN TISSUE; MISMATCH REPAIR; OVARY CANCER; PANCREAS CANCER; PEDIGREE; PRIORITY JOURNAL; SEROUS UTERINE CARCINOMA; UTERUS CARCINOMA;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; CYSTADENOCARCINOMA, SEROUS; DNA MISMATCH REPAIR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASTIC SYNDROMES, HEREDITARY; PEDIGREE; PROGNOSIS; PROSPECTIVE STUDIES; UTERINE NEOPLASMS;

EID: 84859467566     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0499     Document Type: Article

References (50)

1. Moore KN, Fader AN. Uterine papillary serous carcinoma. Clin Obstet Gynecol 2011;54:278-91.
2. Ueda SM, Kapp DS, Cheung MK, Shin JY, Osann K, Husain A, et al. Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 2008;198:218.e1-6.
3. Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006;94:642-6. (Pubitemid 43361894)
4. Fader AN, Boruta D, Olawaiye AB, Gehrig PA. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol 2010;22:21-9.
5. Maxwell GL, Tian C, Risinger J, Brown CL, Rose GS, Thigpen JT, et al. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer 2006;107:2197-205. (Pubitemid 44665654)
6. McCullough ML, Patel AV, Patel R, Rodriguez C, Feigelson HS, Bandera EV, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev 2008;17:73-9. (Pubitemid 351196275)
7. Matthews RP, Hutchinson-Colas J, Maiman M, Fruchter RG, Gates EJ, Gibbon D, et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol 1997;65:206-12. (Pubitemid 27216929)
8. Mendivil A, Schuler KM, Gehrig PA. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control 2009;16:46-52.
9. Bjorge T, Engeland A, Tretli S, Weiderpass E. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer 2007;120:378-83. (Pubitemid 44956850)
10. Fader AN, Starks D, Gehrig PA, Secord AA, Frasure HE, O'Malley DM, et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol 2009;115: 244-8.
11. Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer 2006;16:1897-902. (Pubitemid 44470053)
12. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005;11:6422-30. (Pubitemid 41338978)
13. Zheng W, Cao P, Zheng M, Kramer EE, Godwin TA. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 1996;61:167-74. (Pubitemid 26145719)
14. Odicino FE, Bignotti E, Rossi E, Pasinetti B, Tassi RA, Donzelli C, et al. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int J Gynecol Cancer 2008;18:14-21.
15. Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011;8:261-71.
16. Biron-Shental T, Drucker L, Altaras M, Bernheim J, Fishman A. High incidence ofBRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Eur J Surg Oncol 2006;32:1097-100. (Pubitemid 44774386)
17. Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003;91:463-9. (Pubitemid 38388137)
18. Geisler JP, Sorosky JI, Duong HL, Buekers TE, Geisler MJ, Sood AK, et al. Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma. Gynecol Oncol 2001;83:501-3. (Pubitemid 33139710)
19. Gehrig PA, Bae-Jump VL, Boggess JF, Groben PA, Fowler WCJr, Van Le L. Association between uterine serous carcinoma and breast cancer. Gynecol Oncol 2004;94:208-11. (Pubitemid 38950522)
20. Chan JK, Manuel MR, Cheung MK, Osann K, Husain A, Teng NN, et al. Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes? Gynecol Oncol 2006;102:508-12. (Pubitemid 44376654)
21. Goshen R, Chu W, Elit L, Pal T, Hakimi J, Ackerman I, et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol 2000;79:477-81.
22. Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P, et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol 2007;104:7-10. (Pubitemid 46054134)
23. Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 2009;16:14-22.
24. Ivanovich JL, Babb SA, Goodfellow PJ, Mutch DG, Herzog TJ, Herzog J, Rader J, et al. Evaluation of the family history collection process and the accuracy of cancer reporting among a cohort of women with endometrial cancer. Clin Cancer Res 2002;8:1849-56. (Pubitemid 34633745)
25. Lu KH. Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis. Fam Cancer 2008;7:53-8.
26. SEER 17 Database. Surveillance Epidemiology and End Results (SEER) Program Research Data (1973-2004), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission.
27. SEER Surveillance Research Program. Available from: www.seer. cancer.gov. SEER*Stat Database: National Cancer Institute SEER*-Stat software V.6.5.2. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
28. Sahai H, Khurshid A. Confidence intervals for the mean of a Poisson distribution: a review. Biometrical J 1993;35:857-67.
29. Sahai H, Khurshid A. Statistics in epidemiology: methods, techniques and applications. Boca Raton, FL: CRC Press, Inc; 1996. p. 172-3. Chap 9 Prospective (Cohort) Studies with Person-Time Data.
30. Rothman KJ, Greenland S. Modern epidemiology, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. p. 242. Chap 14 Introduction to Categorical Statistics.
31. Efron B, Tibshirani R. An introduction to bootstrap. In: Hall CA, editor. London, UK: Chapman and Hall; 1993. p. 153-4. Chap 12 Confidence intervals based on bootstrap "tables".
32. Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006;66:7810-7. (Pubitemid 44289242)
33. Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005;293:1979-85. (Pubitemid 40570891)
34. Sandles LG, Shulman LP, Elias S, Photopulos GJ, Smiley LM, Posten WM, et al. Endometrial adenocarcinoma: genetic analysis suggesting heritable site-specific uterine cancer. Gynecol Oncol 1992;47:167-71. (Pubitemid 23001323)
35. Lorenzo Bermejo J, Buchner FL, Hemminki K. Familial risk of endometrial cancer after exclusion of families that fulfilled Amsterdam, Japanese or Bethesda criteria for HNPCC. Ann Oncol 2004;15:598-604. (Pubitemid 38559595)
36. Ollikainen M, Abdel-Rahman WM, Moisio AL, Lindroos A, Kariola R, Jarvela I, et al. Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? J Clin Oncol 2005;23:4609-16. (Pubitemid 46224063)
37. Duffy DL, Antill YC, Stewart CJ, Young JP, Spurdle AB. Report of endometrial cancer in Australian BRCA1 and BRCA2 mutation-positive families. Twin Res Hum Genet 2011;14:111-8.
38. Hemminki K, Li X. Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 2003;103:525-30. (Pubitemid 36020229)
39. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91:1310-6.
40. Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, et al. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer 2012;118:493-9.
41. Kim DH, Crawford B, Ziegler J, Beattie MS. Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. Fam Cancer 2009;8:153-8.
42. Hearle N, Schumacher V,Menko FH, Olschwang S, Boardman LA, Gille JJ, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006;12:3209-15. (Pubitemid 43837371)
43. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009;324:217.
44. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995;333:975-7.
45. Bruchim I, Amichay K, Kidron D, Attias Z, Biron-Shental T, Drucker L, et al. BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma. Int J Gynecol Cancer 2010;20:1148-53.
46. Barak F, Milgrom R, Laitman Y, Gemer O, Rabinovich A, Piura B, et al. The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients. Gynecol Oncol 2010;119:511-5.
47. Lavie O, Hornreich G, Ben Arie A, Renbaum P, Levy-Lahad E, Beller U. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol 2000;96:28-32. (Pubitemid 30336275)
48. Ghiorzo P, Pensotti V, Fornarini G, Sciallero S, Battistuzzi L, Belli F, et al. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy. Fam Cancer. 2011 Oct 12. [Epub ahead of print].
49. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
50. Ellisen LW. PARP inhibitors in cancer therapy: promise, progress, and puzzles. Cancer Cell 2011;19:165-7.